Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2017

View Archived Issues

CytomX Therapeutics advances CX-2029, reaching milestone in AbbVie collaboration

New phase I trial explores BI-754111 alone or in combination with BI-754091 in advanced cancer

Atridia conducts phase I study of SHR-1316 in patients with cancer

Patient enrollment begins in phase I/II study of AGTC-402

Pelican Therapeutics makes progress advancing PTX-25

European Commission approves Pfizer's inotuzumab ozogamicin

Clinical activity of larotrectinib may lead to NDA this year

Arthrogen begins phase I trial of ART-I02 in rheumatoid arthritis and active arthritis in the joint

AEterna Zentaris resubmits Macrilen NDA to FDA

TAS-120 shows promise for the treatment of FGFR-aberrant cholangiocarcinoma

Daiichi Sankyo reports topline results from NEUCOURSE and ALDAY studies of mirogabalin

TissueGene receives grant to support development of tonogenchoncel-L

TRX-818 well tolerated in phase I studies in patients with advanced cancer

Novel antibacterials patented by Fondazione Istituto Insubrico Ricerca per la Vita

FDA gives ibalizumab BLA priority review

TriMix-MEL begins phase Ib adjuvant melanoma trial

FDA approves Triptodur for central precocious puberty

Zealand initiates phase III trial of dasiglucagon to treat severe hypoglycemia in diabetes

Auspherix discovers antibacterial gold complexes

National Eye Institute funds research into dry eye

Merck & Co. identifies new muscarinic acetylcholine M1receptor modulators

Shanghai SIMR Biotech identifies new GABA(A) receptor subunit alpha-5 inverse agonists

Somatuline approved in Japan for gastroenteropancreatic neuroendocrine tumors

Roche discovers new gamma-secretase inhibitors

Exscientia collaborates with GSK on drug discovery

Spotlight Innovation enters sponsored research agreement with Brigham and Women's Hospital on SMA

AstraZeneca completes divestiture of Zomig to Grunenthal

SteadyMed submits NDA for Trevyent for PAH

BGB-290 combined with BGB-A317 in solid tumors trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...